IP Library › Granted Patent US 7,622,270
Granted Patent B2
US 7,622,270 · App. 10/532,264 · Granted Nov 24, 2009

Methods of isolating dopaminergic neuron precursor cells

Assignee: Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,270
App. No.
10/532,264
Granted
Nov 24, 2009
Kind
B2
Abstract

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.

Claims (31)

1. A method of selecting a dopaminergic neuron precursor cell, wherein the method comprises:

contacting a cell sample comprising ventral midbrain cells with an antibody that binds to a polypeptide

encoded by a polynucleotide comprising a sequence selected from

(i) a nucleotide sequence comprising nucleotides 178 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2;

(ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4;

(iii) a nucleotide encoding residues 18-700 of SEQ ID NO:3 or residues 18-650 of SEQ ID NO:4

(iv) a nucleotide sequence encoding an amino acid sequence which has 80% or more identity with the amino acid sequence of SEQ ID NO: 3 or 4; and or

a fragment of said polypeptide comprising at least eight amino acid residues; and

isolating the dopaminergic neuron precursor cell, wherein the dopaminergic neuron precursor cell has bound to the antibody.

2. The method according to claim 1 , wherein the method comprises the step of separating the dopaminergic neuron precursor cell by flow cytometry.

3. The method according to claim 1 , wherein the antibody binds to an extracellular region of the polypeptide.

4. The method according to claim 1 , wherein the nucleotide sequence of (iv) encodes a protein having the amino acid sequence having 95% or more identity with the amino acid sequence of SEQ ID NO: 3 or 4.

5. The method according to claim 1 wherein the polypeptide is encoded by a polynucleotide comprising a sequence selected from the group consisting of:

(i) a nucleotide sequence comprising nucleotides 178 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2;

(ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4; and

(iii) a nucleotide encoding residues 18-700 of SEQ ID NO:3 or residues 18-650 of SEQ ID NO:4.

6. A method of producing a cell population comprising dopaminergic neuron precursor cells, wherein the method comprises contacting a cell sample comprising ventral midbrain cells with an antibody that binds to a polypeptide

encoded by a polynucleotide comprising a sequence selected from

(i) a nucleotide sequence comprising nucleotides 178 to 2280 of SEQ ID NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2;

(ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4;

(iii) a nucleotide encoding residues 18-700 of SEQ ID NO:3 or residues 18-650 of SEQ ID NO:4

(iv) a nucleotide sequence encoding an amino acid sequence which has 80% or more identity with the amino acid sequence of SEQ ID NO: 3 or 4; and or

a fragment of said polypeptide comprising at least eight amino acid residues; and

isolating the cell population comprising dopaminergic neuron precursor cells, wherein the dopaminergic neuron precursor cells have bound to the antibody.

7. The method according to claim 6 , wherein the method comprises the step of separating the dopaminergic neuron precursor cell by flow cytometry.

8. The method according to claim 6 , wherein the antibody binds to an extracellular region of the polypeptide.

9. The method according to claim 6 , wherein the nucleotide sequence of (iv) encodes a protein having the amino acid sequence having 95% or more identity with the amino acid sequence of SEQ ID NO: 3 or 4.

10. The method according to claim 6 , wherein the polypeptide is encoded by a polynucleotide comprising a sequence selected from the group consisting of:

(i) a nucleotide sequence comprising nucleotides 178 to 2280 of SEQ ED NO: 1 or nucleotides 127 to 2079 of SEQ ID NO: 2;

(ii) a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or 4; and

(iii) a nucleotide encoding residues 18-700 of SEQ ID NO:3 or residues 18-650 of SEQ ID NO:4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019265/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2005
From: NAKAGAWA, YASUKO; ONO, YUICHI; SAKAMOTO, YOSHIMASA; MIZUHARA, ERI; NAKATANI, TOMOYA; TAKAI, YOSHIMI
To: EISAI CO., LTD.
Reel/Frame 016949/0762 →
Priority Claims (1)
JP 2002-307573 · Oct 22, 2002 · national
Continuity (1)
Related Publication 20060239978A1 · Oct 26, 2006